Form 4: Recursion Pharmaceuticals Director Blake Borgeson Sells Shares Under 10b5-1 Plan

Director Blake Borgeson of Recursion Pharmaceuticals sold 11,447 shares of Class A Common Stock at a weighted average price of $6.8431 per share, executed under a pre-arranged 10b5-1 trading plan.

Summary

• On September 17, 2024, Blake Borgeson, a director at Recursion Pharmaceuticals, sold 11,447 shares of Class A Common Stock.
• The sale was executed at a weighted average price of $6.8431 per share, with individual trades ranging from $6.74 to $7.03.
• The transaction was conducted under a Rule 10b5-1 trading plan adopted on August 18, 2023.
• Following the transaction, Borgeson directly owns 7,109,875 shares of Recursion Pharmaceuticals' Class A Common Stock.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating a routine transaction. The sentiment is neutral as it simply reports the sale of shares.

Industry Context

Sales by insiders are common and can be for a variety of personal financial reasons. The use of a 10b5-1 plan suggests the insider is selling shares in a pre-planned manner to avoid accusations of trading on inside information.

Stakeholder Impact

• The sale of shares by a director could be perceived negatively by some investors, potentially leading to a slight decrease in stock price, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates